You are on page 1of 7

Arrhythmia/Antiarrhythmic Drugs-Test-3-Questions

1 Class I antiarrhythmic: similar to quinidine gluconate (Quinaglute, Quinalan); greater antimuscarinic

effects compared to quinidine; approved use (USA) ventricular arrhythmias:

A) lidocaine (Xylocaine)

B) procainamide (Procan SR, Pronestyl-SR)

C) disopyramide (Norpace)

D) mexiletine (Mexitil)

E) tocainide (Tonocard)

2 Beta adrenergic receptor blockers:

A) increased AV conduction time

B) decreased AV nodal refractoriness

C) both

D) neither

3 Particularly effective in suppressing ventricular arrhythmias associated with digitalis toxicity:

A) lidocaine (Xylocaine)

B) quinidine gluconate (Quinaglute, Quinalan)

C) procainamide (Procan SR, Pronestyl-SR)

D) phenytoin (Dilantin)

E) esmolol (Brevibloc)

4 (Multiple Answer) Mechanism(s) of quinidine gluconate (Quinaglute, Quinalan) antiarrhythmic effect:

A) depresses ectopy
B) decreases conduction velocity

C) decreases excitability

5 Very short-acting, cardioselective beta adrenergic receptor antagonist:

A) propranolol (Inderal)

B) metoprolol (Lopressor)

C) esmolol (Brevibloc)

D) adenosine (Adenocard)

E) theophylline

6 Shortens QT interval more than any other antiarrhythmic drug:

A) lidocaine (Xylocaine)

B) phenytoin (Dilantin)

C) mexiletine (Mexitil)

D) esmolol (Brevibloc)

E) adenosine (Adenocard)

7 Major clinical antiarrhythmic use of calcium channel blockers:

A) ventricular arrhythmias

B) reentrant supraventricular tachycardia

C) both

D) neither

8 Basis for quinidine gluconate (Quinaglute, Quinalan)-mediated longer action potential duration:

A) reduces outward potassium current

B) increases outwardpotassium current

9 Antiarrhythmic drug: may cause hypothyroidism or hyperthyroidism (frequency -- 2%-4%): approved

for use only in the treatment of serious ventricular arrhythmias (USA); also use for refractory
supraventricular arrhythmias

A) mexiletine (Mexitil)

B) tocainide (Tonocard)

C) adenosine (Adenocard)

D) amiodarone (Cordarone)

E) procainamide (Procan SR, Pronestyl-SR)

10 Antiarrhythmic drug: 37% iodine by weight, structurally similar to thyroxine:

A) propranolol (Inderal)

B) mexiletine (Mexitil)

C) flecainide (Tambocor)

D) amiodarone (Cordarone)

E) esmolol (Brevibloc)

11 (Multiple Answer) Side effects/toxicities: disopyramide (Norpace)

A) negative inotropism -- very significant

B) dry mouth

C) urinary hesitancy

D) paradoxical ventricular tachycardia

E) QT interval prolongation (ECG)

12 Effect of quinidine gluconate (Quinaglute, Quinalan) on digoxin (Lanoxin, Lanoxicaps) plasma

A) increases digoxin (Lanoxin, Lanoxicaps) levels

B) decreases digoxin (Lanoxin, Lanoxicaps) levels

13 Fluorinated local anesthetic analog of procainamide:

A) tocainide (Tonocard)

B) lidocaine (Xylocaine)

C) flecainide (Tambocor)

D) disopyramide (Norpace)

E) none of the above

14 (Multiple Answer) Side effects associated with quinidine gluconate (Quinaglute, Quinalan)

A) prolongation PR interval

B) syncope

C) bradycardia (SA nodal)

D) hypotension

E) positive inotropism

15 (Multiple Answer) Concerning procainamide (Procan SR, Pronestyl-SR)-induced lupus erythematosus-

like syndrome:

A) include serositis, arthralgia, arthritis

B) includes vasculitis

C) irreversible

D) positive antinuclear antibody test -- common

16 Amine lidocaine analog-- orally active, really used because of possibly fatal bone marrow aplasia and
pulmonary fibrosis:
A) mexiletine (Mexitil)

B) tocainide (Tonocard)

C) quinidine gluconate (Quinaglute, Quinalan)

D) procainamide (Procan SR, Pronestyl-SR)

E) esmolol (Brevibloc)

17 Antiarrhythmic drug which is a local anesthetic analog and which with long-term use may cause a
lupus-related side effect--

A) lidocaine (Xylocaine)

B) disopyramide (Norpace)

C) procainamide (Procan SR, Pronestyl-SR)

D) diltiazem (Cardiazem)

E) mexiletine (Mexitil)

18 Major noncardiac side effect of lidocaine (Xylocaine):

A) hepatic

B) renal

C) pulmonary


E) endocrine

19 Comparing quinidine gluconate (Quinaglute, Quinalan) and procainamide (Procan SR, Pronestyl-SR):
this drug more likely to produce antimuscarinic and hypotensive reactions

A) quinidine gluconate (Quinaglute, Quinalan)

B) procainamide (Procan SR, Pronestyl-SR)

20 Local anesthetic administered by IV for management of ventricular arrhythmias:

A) quinidine gluconate (Quinaglute, Quinalan)

B) procainamide (Procan SR, Pronestyl-SR)

C) lidocaine (Xylocaine)

D) flecainide (Tambocor)

E) adenosine (Adenocard)

21 Sodium channel blocker -- antiarrhythmic drug that slows the rate of action potential rise and
prolongs ventricular effective refractory period

A) lidocaine (Xylocaine)-type 1b

B) quinidine gluconate (Quinaglute, Quinalan)-type 1a

C) flecainide (Tambocor)-type 1c

22 Nonselective beta adrenergic receptor blocker that also blocks potassium currents

A) esmolol (Brevibloc)

B) propranolol (Inderal)

C) metoprolol (Lopressor)

D) sotalol (Betapace)

E) labetalol (Trandate, Normodyne)

23 Lidocaine (Xylocaine):

A) greater effect on supraventricular tachyarrhythmias

B) greater effect on ventricular arrhythmias

24 Quinidine effects on neuromuscular transmission:

A) augments
B) interferes

25 Possesses antimalarial antipyretic properties:

A) flecainide (Tambocor)

B) esmolol (Brevibloc)

C) quinidine gluconate (Quinaglute, Quinalan)

D) procainamide (Procan SR, Pronestyl-SR)

E) disopyramide (Norpace)

26 Most serious adverse effect with long-term treatment: rapidly progressive pulmonary
fibrosis:frequency: 5%-15%

A) lidocaine (Xylocaine)

B) propranolol (Inderal)

C) amiodarone (Cordarone)

D) procainamide (Procan SR, Pronestyl-SR)

27 (True/False) Quinidine gluconate (Quinaglute, Quinalan) effect on the ECG: QT interval lengthening

A) true

B) false

28 (Multiple Answer) Clinical uses for quinidine gluconate (Quinaglute, Quinalan):

A) prevent recurrence of supraventricular tachyarrhythmias

B) ventricular tachycardia

C) atrial fibrillation

D) atrial flutter